A partnership led by the Medical Research Council (MRC) has awarded the University of Cambridge £25 million to provide cutting-edge equipment and infrastructure for its clinical research. Within this award, was specific funding to enable the creation of the Cambridge Single Cell Analysis Clinical Core Facility, a new shared core facility for single cell analysis that will serve all major molecular medicine programmes in Cambridge: cancer, neurosciences, immunity and inflammation, infectious diseases, stem cell and regenerative medicine, metabolic medicine and experimental therapeutics.
Themes within this award will focus on repair and regeneration of musculoskeletal system. This approach will allow a fundamental understanding of cell behaviour, where the cell can be considered as either the treatment (cell therapy) or the target for treatment (molecules and materials).